Immunosuppresant; E3 UB ligase inhibitor. Limits 'cytokine storm' induced by SARS-CoV-2. Chen et al. Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia, Preprints 2020: 2020020395, Feb 26 2020, https://www.preprints.org/manuscript/202002.0395/v1.
- Datasheet: view or download
- Applications:"Cytokine storm" drug (approved, U.S.), in COVID-19 clinical trials
Biochemicals & reagents
1) Ito et al. (2010), Identification of a primary target of thalidomide teratogenicity; Science, 327 1345 / 2) Weglicki et al. (1993), Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency; Mol. Cell. Biochem., 129 195 / 3) D’Amato et al. (1994), Thalidomide is an inhibitor of angiogenesis ; Proc. Natl. Acad. Sci. USA, 91 4082
Thalidomide binds to the E3 ubiquitin ligase complex formed between CRBN, DDB1 and Cul4A, and inhibits the ligase activity. It also inhibits TNF synthesis and FGF-induced angiogenesis. This compound is cell permeable and should be handle with caution as it is teratogenic.